Format

Send to

Choose Destination
Lancet Oncol. 2004 Sep;5(9):531-40.

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

Author information

1
Clinical Trial Unit, Department of Pulmonology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium. johan.vansteenkiste@uz.kuleuven.ac.be

Abstract

Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [(18)F]FDG uptake on PET has independent prognostic value in newly diagnosed non-small-cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [(18)F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [(18)F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [(18)F]FDG-PET over CT in the correct identification of recurrent lung cancer.

PMID:
15337482
DOI:
10.1016/S1470-2045(04)01564-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center